PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21854184-0 2012 Combination of midazolam and a cyclooxygenase-2 inhibitor inhibits lipopolysaccharide-induced interleukin-6 production in human peripheral blood mononuclear cells. Midazolam 15-24 interleukin 6 Homo sapiens 94-107 21854184-2 2012 Midazolam has been reported to modulate IL-6 response. Midazolam 0-9 interleukin 6 Homo sapiens 40-44 21854184-5 2012 OBJECTIVE: The aim of the present study was to evaluate the effect of the combination of midazolam and a COX inhibitor on IL-6 production. Midazolam 89-98 interleukin 6 Homo sapiens 122-126 21854184-11 2012 DISSCUSSION AND CONCLUSION: The results in the present study demonstrated that the combination of midazolam and a COX-2 inhibitor inhibited LPS-induced IL-6 production in human PBMCs even if each drug separately did not have any effect on it. Midazolam 98-107 interleukin 6 Homo sapiens 152-156 21854184-12 2012 The finding suggests that their combination is effective against excessive IL-6 production such as severe inflammatory response and that the effect of midazolam on IL-6 production is possibly elicited via 15dPGJ2. Midazolam 151-160 interleukin 6 Homo sapiens 164-168 1955561-3 1991 injection of 0.08 mg/kg midazolam induced a marked and delayed inhibition of the lipopolysaccharide-induced production of interleukin-1 beta, tumor necrosis factor-alpha and interleukin-6 by monocytes isolated from peripheral blood. Midazolam 24-33 interleukin 6 Homo sapiens 174-187 11594799-0 2001 Effect of midazolam on interleukin-6 mRNA expression in human peripheral blood mononuclear cells in the absence of lipopolysaccharide. Midazolam 10-19 interleukin 6 Homo sapiens 23-36 11594799-3 2001 The purpose of the present study was to evaluate the effect of midazolam on interleukin-6 (IL-6) response by observing mRNA expression levels in human peripheral blood mononuclear cells (PBMCs) in the absence of lipopolysaccharide (LPS). Midazolam 63-72 interleukin 6 Homo sapiens 76-89 11594799-3 2001 The purpose of the present study was to evaluate the effect of midazolam on interleukin-6 (IL-6) response by observing mRNA expression levels in human peripheral blood mononuclear cells (PBMCs) in the absence of lipopolysaccharide (LPS). Midazolam 63-72 interleukin 6 Homo sapiens 91-95 11594799-7 2001 It was found that midazolam time-dependently inhibited the IL-6 mRNA expression in PBMCs in the absence of LPS, and significantly inhibited the IL-6 mRNA expression at 1 microg/ml (P<0.05) or 10 microg/ml (P<0.01) in the absence of LPS. Midazolam 18-27 interleukin 6 Homo sapiens 59-63 11594799-7 2001 It was found that midazolam time-dependently inhibited the IL-6 mRNA expression in PBMCs in the absence of LPS, and significantly inhibited the IL-6 mRNA expression at 1 microg/ml (P<0.05) or 10 microg/ml (P<0.01) in the absence of LPS. Midazolam 18-27 interleukin 6 Homo sapiens 144-148 11594799-9 2001 These findings indicated a suppression of the IL-6 response in human PBMCs by midazolam in the absence of LPS, and suggests that midazolam has its effect not via benzodiazepine receptors, but by another mechanism. Midazolam 78-87 interleukin 6 Homo sapiens 46-50 11594799-9 2001 These findings indicated a suppression of the IL-6 response in human PBMCs by midazolam in the absence of LPS, and suggests that midazolam has its effect not via benzodiazepine receptors, but by another mechanism. Midazolam 129-138 interleukin 6 Homo sapiens 46-50 26345937-7 2015 This inhibition was concentration-dependent between 0.3 and 3 muM, with 3 muM concentration of midazolam decreasing the IL-1beta-induced release of IL-6 by 43.58%. Midazolam 95-104 interleukin 6 Homo sapiens 148-152 34078115-6 2022 IL-6 inhibitors (sirukumab, tocilizumab, sarilumab) significantly enhance metabolism via CYP2C9 (s-warfarin), CYP2C19 (omeprazole), and CYP3A4 (simvastatin, midazolam) and reduce metabolism via CYP1A2 (caffeine). Midazolam 157-166 interleukin 6 Homo sapiens 0-4 34581012-5 2022 Upon blockade of the IL-6 signaling pathway by an anti-IL-6 treatment, the AUCs of S-warfarin, omeprazole and midazolam were predicted to decrease by up to 40%, 42%, and 46%, respectively. Midazolam 110-119 interleukin 6 Homo sapiens 21-25 34581012-5 2022 Upon blockade of the IL-6 signaling pathway by an anti-IL-6 treatment, the AUCs of S-warfarin, omeprazole and midazolam were predicted to decrease by up to 40%, 42%, and 46%, respectively. Midazolam 110-119 interleukin 6 Homo sapiens 55-59 34496043-6 2022 Subsequently, the verified model was used to simulate the effect of various clinically observed IL-6 levels on the exposure of LPV/r and midazolam, a CYP3A model drug. Midazolam 137-146 interleukin 6 Homo sapiens 96-100 35397768-4 2022 To develop a population pharmacokinetic model for midazolam in adult intensive care unit patients infected with COVID-19 and to assess the effect of inflammation, reflected by IL-6, on the pharmacokinetics of midazolam. Midazolam 209-218 interleukin 6 Homo sapiens 176-180 35397768-12 2022 Midazolam clearance was reduced by increased IL-6 and IL-6 explained more of the variability within our patients than CRP. Midazolam 0-9 interleukin 6 Homo sapiens 45-49 35397768-12 2022 Midazolam clearance was reduced by increased IL-6 and IL-6 explained more of the variability within our patients than CRP. Midazolam 0-9 interleukin 6 Homo sapiens 54-58 35397768-13 2022 The midazolam clearance was reduced by 24% (6.7-5.1 L/h) when IL-6 increases from population median 116 to 300 pg/mL. Midazolam 4-13 interleukin 6 Homo sapiens 62-66 35397768-14 2022 CONCLUSIONS: Inflammation, reflected by high IL-6, reduces midazolam clearance in critically ill patients with COVID-19. Midazolam 59-68 interleukin 6 Homo sapiens 45-49 30887238-1 2019 A physiologically based pharmacokinetic (PBPK) model was used to simulate the impact of elevated levels of interleukin (IL)-6 on the exposure of several orally administered cytochrome P450 (CYP) probe substrates (caffeine, S-warfarin, omeprazole, dextromethorphan, midazolam, and simvastatin). Midazolam 265-274 interleukin 6 Homo sapiens 107-125 30530051-7 2019 RESULTS: Midazolam suppressed LPS-induced upregulation of CD80 and release of IL-6 and NO in THP-1 cells and PMDMs. Midazolam 9-18 interleukin 6 Homo sapiens 78-82 26961818-6 2016 The results suggested that, compared with observed clinical data, changes in systemic exposure to multiple CYP substrates by anti-IL-6 treatment in virtual RA patients have been reasonably captured by the PBPK model, as manifested by modulations in area under plasma concentration versus time curves for midazolam, omeprazole, S-warfarin, and caffeine. Midazolam 304-313 interleukin 6 Homo sapiens 130-134 29794481-7 2018 Moreover, the midazolam group exhibited lower oxidative stress markers with a higher fold change in IL-6 and TNF-alpha mRNA levels. Midazolam 14-23 interleukin 6 Homo sapiens 100-104 27722854-9 2017 CONCLUSIONS: Sarilumab treatment resulted in a reduction in exposure of simvastatin, consistent with reversal of IL-6-mediated CYP3A4 suppression in patients with active RA, as was reported for tocilizumab with simvastatin and for sirukumab with midazolam. Midazolam 246-255 interleukin 6 Homo sapiens 113-117 25591756-12 2015 But IL-6 could counteract the anti-apoptotic effects of MDZ. Midazolam 56-59 interleukin 6 Homo sapiens 4-8